Search:
Toggle Navigation
Search:
About Us
Our Company
Management Team
Board of Directors
Clinical Advisory Board
Contact Us
Product Candidates
Our Pipeline
Preclinical Candidates
Clinical Trials
Science
LANCE Precision Medicine Platform
Immuno
–
metabolic Pathways
Publications
Investors/Media
Investor/Media Home
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Investors/Media FAQs
Careers
Why Landos?
Open Positions
News
8/20
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Trials of BT-11 in Ulcerative Colitis
Read More
8/13
Landos Biopharma Raises $60 Million in Series B Financing
Read More
5/15
Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers
Read More
3/05
Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11
Read More
2/21
Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD
Read More
1/14
Dr. Bassaganya-Riera, Landos Chairman & CEO, Provides Corporate and Clinical Update
Read More
« Previous
1
2
3
4
…
6
Next »
